Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Cochlear Hearing Loss

imatinib mesylate has been researched along with Cochlear Hearing Loss in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kay, J; Lin, HW; Roberts, DS; Stankovic, KM1
DesJardins, A; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ1
Anupama, G; Attili, VS; Bapsy, PP; Lokanatha, D1

Other Studies

3 other study(ies) available for imatinib mesylate and Cochlear Hearing Loss

ArticleYear
Sensorineural hearing loss following imatinib (Gleevec) administration.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2012, Volume: 146, Issue:2

    Topics: Benzamides; Female; Hearing Loss, Sensorineural; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2012
Neurofibromatosis type 2.
    Neurology, 2007, Mar-27, Volume: 68, Issue:13

    Topics: Antineoplastic Agents; Benzamides; Cochlear Nerve; Female; Functional Laterality; Hearing Loss, Sensorineural; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Piperazines; Pyrimidines; Treatment Outcome; Vestibular Nerve

2007
Irreversible sensorineural hearing loss due to Imatinib.
    Leukemia research, 2008, Volume: 32, Issue:6

    Topics: Adult; Benzamides; Hearing Loss, Sensorineural; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines

2008